Clinical Trials Using FGFR Inhibitor Debio 1347

Clinical trials are research studies that involve people. The clinical trials on this list are studying FGFR Inhibitor Debio 1347. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

    The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion / rearrangement.
    Location: 12 locations

  • Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

    This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 genes, for whom standard treatment does not exist or is not indicated. The main objective of Part A is to identify the dose-limiting toxicities (DLTs) and estimate the maximum tolerated dose (MTD) based on the safety and tolerability of Debio1347 orally administered daily to these patients, in order to determine the recommended dose. The main objective of Part B is to evaluate the safety profile at the recommended dose, in a larger cohort of these patients.
    Location: 5 locations

  • FGFR Inhibitor Debio 1347 and Fulvestrant in Treating Patients with FGFR-Amplified Endocrine Receptor Positive Metastatic Breast Cancer

    This phase Ib / II trial studies the side effects and best dose of FGFR inhibitor Debio 1347 when given together with fulvestrant and to see how well they work in treating patients with FGFR-amplified endocrine receptor positive breast cancer that has spread to other places in the body (metastatic). FGFR inhibitor Debio 1347 may block some receptors that needed for cell growth. Estrogen can cause the growth of breast cancer cells. Drugs, such as fulvestrant, may lessen the amount of [hormone] made by the body. Giving FGFR inhibitor Debio 1347 and fulvestrant may work better in treating patients with FGFR-amplified endocrine receptor positive breast cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York